In conclusion, our results indicate that DMRGM are common in AML patients and adversely impact the prognosis of AML patients, particularly those in the 2017 ELN favorable risk group defined by mutated NPM1. The latter patients had OS similar to that of patients in the ELN adverse risk group. Here, NPM1 is linked to acute myeloid leukemia.